This site uses cookies to improve user experience by collecting data. By continuing to use this website, you agree to the use of cookies and similar technologies as described in our Privacy Policy.
CONFIRM

γδ T cells

Eliciting a Robust Anticancer Immune Response
Acepodia’s nature killer γδ cell program harnesses the unique properties of γδ  T cells to develop a new class of off-the-shelf cell therapies for the treatment of cancer. γδ T cells have characteristics of both the innate and adaptive immune systems that make them an ideal chassis for the development of cell therapies. This cell type can directly recognize and attack cancerous cells as well as coordinate a broad antitumor immune response by recruiting and activating other immune factors and cells to the site of disease. γδ T cells have also been shown to preferentially traffic to distinct tissues and could be ideally suited for more targeted treatment of certain types of cancers.
iStock-1159809744
PLAY VIDEO
A Unique, Powerful Cancer-Fighting Cell
Advantages of Acepodia’s γδ T Cell Technology

Advantages of Acepodia’s γδ T Cell Technology

Acepodia has developed a unique γδ T cells that are enriched to provide the added benefits of NK functions through its proprietary selection and expansion technology. The γδ T cells express high level of NK activating receptors such as CD56 and NKG2D and low level of inhibitory receptors, enhancing potency to directly kill the tumor cells and indirectly activate other immune factors against the malignancy. Unlike traditional T cell therapies, γδ T cells can be administered off-the-shelf and do not need to be tailored for each individual patient, allowing for a streamlined manufacturing process and broader potential use. While an attractive candidate for cell therapies, gamma delta T cells only represent a small fraction of circulating T cells which has greatly limited their use in the past.
Realizing the Promise of γδ T Cells

Realizing the Promise of γδ T Cells

Acepodia is overcoming the limited nature of γδ T cells by developing a proprietary allogeneic γδ T cell production that represents a consistent and scalable source of γδ T cells. Using its integrated approach, Acepodia is enhancing its γδ T cells for the development of therapies that can complement its other cell therapy programs.

Guiding γδ T Cells Directly to Tumor Sites: ACC

Currently available cell therapies also present challenges in effectively engaging cancer cells due to immunosuppression caused by the tumor microenvironment. By uniting its potent γδ T cells with well-established, as well as proprietary and novel tumor-targeting mechanisms, Acepodia’s cell therapy candidates are designed to target cancer cells and overcome tumor defenses to deliver their potent, cancer-killing cellular payload.

PIPELINE

PROMISING PIPELINE OF CELL THERAPIES

ACC

Program
Discovery
Preclinical
Phase I
Phase II
ACE1831
CD20 Targeting, ACC-γδ T Cell Therapy
Preclinical ​
ACE1708
PD-L1 Targeting, ACC-γδ T Cell Therapy
Preclinical ​
ACE1975
Target undisclosed, ACC-γδ T Cell Therapy
Preclinical ​
ACE2023
Target undisclosed, ACC-γδ T Cell Therapy
Preclinical ​
We have collaborated with biopharmaceutical partners and academic institutes worldwide.